|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 1 (January 1), 1999:
pp. 51-54
Age Is Not a Prognostic Variable With Autotransplants for Multiple
Myeloma
D.S. Siegel,
K.R. Desikan,
J. Mehta,
S. Singhal,
A. Fassas,
N. Munshi,
E. Anaissie,
S. Naucke,
D. Ayers,
D. Spoon,
D. Vesole,
G. Tricot, and
B. Barlogie
From the Myeloma and Transplantation Research Center, University of
Arkansas for Medical Sciences and Arkansas Cancer Research Center,
Little Rock.
Multiple myeloma (MM) typically afflicts elderly patients with a
median age of 65 years. However, while recently shown to provide
superior outcome to standard treatment, high-dose therapy (HDT) has
usually been limited to patients up to 65 years. Among 550 patients
with MM and a minimum follow-up of 18 months, 49 aged  65 years were
identified (median age, 67; range, 65 to 76 years). Their outcome was
compared with 49 younger pair mates (median, 52; range, 37 to 64 years)
selected among the remaining 501 younger patients (<65 years) matched
for five previously recognized critical prognostic factors
(cytogenetics,  2-microglobulin, C-reactive protein,
albumin, creatinine). Nearly one half had been treated for more than 1 year with standard therapy and about one third had refractory MM. All
patients received high-dose melphalan-based therapy; 76% of the
younger and 65% of the older group completed a second transplant
(P = .3). Sufficient peripheral blood stem cells to support
two HDT cycles (CD34 > 5 × 106/kg) were available
in 83% of younger and 73% of older patients (P = .2).
After HDT, hematopoietic recovery to critical levels of granulocytes
(>500/µL) and of platelets (>50,000/µL) proceeded at comparable
rates among younger and older subjects with both first and second HDT.
The frequency of extramedullary toxicities was comparable.
Treatment-related mortality with the first HDT cycle was 2% in younger
and 8% among older subjects, whereas no mortality was encountered with
the second transplant procedure. Comparing younger/older subjects,
median durations of event-free and overall survival were 2.8/1.5 years
(P = .2) and 4.8/3.3 years (P = .4).
Multivariate analysis showed pretransplant cytogenetics and
2-microglobulin levels as critical prognostic features
for both event-free and overall survival, whereas age was insignificant for both endpoints (P = .2/.8). Thus, age is not a
biologically adverse parameter for patients with MM receiving high-dose
melphalan-based therapy with peripheral blood stem cell support and,
hence, should not constitute an exclusion criterion for participation
in what appears to be superior therapy for symptomatic MM.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. J. Lahuerta, M. V. Mateos, J. Martinez-Lopez, L. Rosinol, A. Sureda, J. de la Rubia, J. Garcia-Larana, R. Martinez-Martinez, M. T. Hernandez-Garcia, D. Carrera, et al.
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
J. Clin. Oncol.,
December 10, 2008;
26(35):
5775 - 5782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ludwig, B. G. M. Durie, V. Bolejack, I. Turesson, R. A. Kyle, J. Blade, R. Fonseca, M. Dimopoulos, K. Shimizu, J. San Miguel, et al.
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
Blood,
April 15, 2008;
111(8):
4039 - 4047.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Seldin, J. J. Anderson, M. Skinner, K. Malek, D. G. Wright, K. Quillen, K. Finn, B. Oran, and V. Sanchorawala
Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
Blood,
December 1, 2006;
108(12):
3945 - 3947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Fermand, S. Katsahian, M. Divine, V. Leblond, F. Dreyfus, M. Macro, B. Arnulf, B. Royer, X. Mariette, E. Pertuiset, et al.
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe
J. Clin. Oncol.,
December 20, 2005;
23(36):
9227 - 9233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Gertz
Too old for transplantation: think again
Blood,
November 15, 2004;
104(10):
3000 - 3001.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley
Treatment of multiple myeloma
Blood,
January 1, 2004;
103(1):
20 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Blade, D. H. Vesole, and M. Gertz
Transplantation for multiple myeloma: who, when, how often?
Blood,
November 15, 2003;
102(10):
3469 - 3477.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney, A. J. Molina, F. Sahebi, K. E. Stockerl-Goldstein, B. M. Sandmaier, W. Bensinger, B. Storer, U. Hegenbart, G. Somlo, T. Chauncey, et al.
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
Blood,
November 1, 2003;
102(9):
3447 - 3454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mileshkin, J. J. Biagi, P. Mitchell, C. Underhill, A. Grigg, R. Bell, J. McKendrick, P. Briggs, J. F. Seymour, K. Lillie, et al.
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
Blood,
July 1, 2003;
102(1):
69 - 77.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar, M. A. Gertz, R. A. Kyle, P. R. Greipp, and Mayo Clinic Myeloma, Amyloid, and Dysproteinemia G
Current Therapy for Multiple Myeloma
Mayo Clin. Proc.,
August 1, 2002;
77(8):
813 - 822.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F.-C. Lee ; and M. Zangari
Second response to lower-dose thalidomide in a patient with multiple myeloma
Blood,
May 13, 2002;
99(11):
4248 - 4249.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Imrie, R. Esmail, R. M. Meyer, and and the Members of the Hematology Disease Site Gro
The Role of High-Dose Chemotherapy and Stem-Cell Transplantation in Patients with Multiple Myeloma: A Practice Guideline of the Cancer Care Ontario Practice Guidelines Initiative
Ann Intern Med,
April 16, 2002;
136(8):
619 - 629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman
Multiple Myeloma
Hematology,
January 1, 2002;
2002(1):
214 - 240.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. A. Zaidi and D. H. Vesole
Multiple Myeloma: An Old Disease with New Hope for the Future
CA Cancer J Clin,
September 1, 2001;
51(5):
273 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Zaucha, C. Yu, G. Mathioudakis, K. Seidel, G. Georges, G. Sale, M.-T. Little, B. Torok-Storb, and R. Storb
Hematopoietic responses to stress conditions in young dogs compared with elderly dogs
Blood,
July 15, 2001;
98(2):
322 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau
Multiple Myeloma
Hematology,
January 1, 2001;
2001(1):
157 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Baynes, C. Hamm, R. Dansey, J. Klein, L. Cassells, C. Karanes, E. Abella, and W. P. Peters
Bone Marrow and Peripheral Blood Hematopoietic Stem Cell Transplantation: Focus on Autografting
Clin. Chem.,
August 1, 2000;
46(8):
1239 - 1251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lenhoff, M. Hjorth, E. Holmberg, I. Turesson, J. Westin, J. L. Nielsen, F. Wisloff, L. Brinch, K. Carlson, M. Carlsson, et al.
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study
Blood,
January 1, 2000;
95(1):
7 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Palumbo, S. Triolo, C. Argentino, S. Bringhen, A. Dominietto, C. Rus, P. Omede, C. Tarella, A. Pileri, and M. Boccadoro
Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients
Blood,
August 15, 1999;
94(4):
1248 - 1253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
